

****Published May 2019****

MarketVIEW: *Staphylococcus aureus* BSI/SSI vaccines (CAT: VAMV002)

Product Name	:	MarketVIEW: <i>Staphylococcus aureus</i> BSI/SSI vaccine (USA)
Description	:	<i>Staphylococcus aureus</i> vaccines: USA commercial analysis, USA market forecast and size
Contents	:	Executive presentation (~195 slides .pdf) + 1 MS Excel workbook (.xls)
Therapeutic Area	:	New/hospital vaccines
Publication date	:	May 2019
Catalogue No	:	VAMV002

Background

Staphylococcus aureus is a Gram-positive toxin-forming bacterium that is a widespread human commensal and pathogen. Approximately 30-60% of the population is colonised either permanently or intermittently. *S.aureus* (SA) is responsible for a wide range of clinical syndromes ranging from high mortality bloodstream infections (BSIs) to community-based skin and soft tissue infections such as skin abscesses (SSTIs). SA is a common cause of healthcare-associated infections (HAIs) such as pneumonia and surgical site infections (SSIs). An antibiotic-resistant form of *S.aureus* (**MRSA**) has become a major problem both in and out of the hospital with an estimated ~88-90K infections occurring in the USA each year with substantial economic burden.

There has been progress in reducing hospital-onset *S.aureus* infections due to improved monitoring and hygiene practices. However, the onset (or acquisition) of infection in the community still presents a challenge to healthcare systems. SA vaccines which prevent and/or reduce the impact of SA infections are greatly needed although it is becoming accepted that a universal vaccine to impact upon all infection types and reduce colonisation is an optimistic goal. Development has been thwarted with numerous failures. Recently, Pfizer vaccines were developing **SA4Ag**, a multicomponent vaccine (reached Phase IIb, fast track designation) to address SA BSI and SSIs in surgical patients undergoing elective open posterior spinal fusion procedures.

This **MarketVIEW** product consists of a detailed Executive presentation (~195 .pdf slides) and comprehensive MS-Excel workbook (.xls) which forecast the potential commercial value of a *S.aureus* "healthcare-associated" vaccine to target BSIs and SSIs in US surgical and End-stage renal disease patients (ESRD) in the US to 2030. For surgery patients, there is a sophisticated uptake methodology whereby specific surgical procedures are assigned a priority level along with an assessment of US state (group of) HO-MRSA risk. Efforts have been made to account for complex overlapping datasets so that discrete numbers of procedures can be forecast as eligible vaccine populations. The analysis also provides a detailed review of latest *S.aureus* (MRSA) US epidemiology (EIP, NHSN)¹, prevention/legislative efforts (HHS Action Plan), vaccinology and current R&D approaches/activity. **MarketVIEW: *Staphylococcus aureus* BSI/SSI vaccine (USA)** lays a solid groundwork designed to initiate or challenge any internal client assessment of this exciting but challenging commercial opportunity.

¹ CDC Emerging Infections Program (CDC), National Healthcare Safety Network (NHSN)

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to US *Staphylococcus aureus*/MRSA epidemiology, hospital in-patient datasets, vaccine development, competitive environment, recommendations, policy. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings, news articles, expert comment etc.

PRODUCT CONTENTS:

Published May 2019 (CAT No: VAMV002)

****This product is a [summary presentation \(.pdf\)](#), [a forecast model \(.xls\)](#)

Contents – Summary presentation (.pdf)²

Contents

Author's notes

Executive summary

[SECTION 1] Staphylococcus aureus BSI/SSI vaccines: key commercial model outputs

[SECTION 2] Staphylococcus aureus: disease background and epidemiology (USA)

[SECTION 3] Staphylococcus aureus: disease epidemiology – analysis of EIP 2005-2016 dataset

[SECTION 4] Staphylococcus aureus: disease epidemiology – analysis of NHSN 2011-2017 dataset

[SECTION 5] Staphylococcus aureus: HAIs, current progress in prevention and control

[SECTION 6] Staphylococcus aureus: the need and potential role for a vaccine

[SECTION 7] Staphylococcus aureus: designing the ideal vaccine approach

[SECTION 8] Staphylococcus aureus: vaccine R&D pipeline

[SECTION 9] Staphylococcus aureus: modelling vaccine commercial potential (USA)

[Appendix I] Staphylococcus aureus: review of clinical syndromes

[Appendix II] Staphylococcus aureus: historical/back-up epidemiological data

About **VacZine Analytics**

Disclaimer

SNAPSHOT

PAGES: ~195 slides fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Worksheets = >60 interconnected

² Full contents i.e. title per slide is proprietary and only available upon valid request

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT (All deliverables) - USD **\$10,995**/ GBP **£8,450**[#] (Region license)*

[#] Indicative company rate only. Prevailing rate applied to the date of transaction.

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to the final invoice total

Agency/consultancy rates (commercial use) are available upon request

HOW TO ORDER:


To order, please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased online. Please review the **TERMS** and **CONDITIONS** of purchase.



BIBLIOGRAPHY

~180 references are included in this study



TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (a division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased online invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars, or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees, and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

of division of Assay Advantage Ltd
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 813155
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009